Mario Branciforti

AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.

The evolution of manufacturing starts from solving the most demanding industrial needs: building large, complex, critical parts with more efficiency and sustainability. Caracol was born from the idea of pushing the limits of manufacturing, beyond what was possible. We brought that idea to life, combining robotics and additive manufacturing into a turnkey solution, which evolves the possibilities of production in terms of scale, shape, and materials. We developed integrated robotic platforms Heron and Vipra – which combine software, hardware, and automation – to manufacture parts with additive processes such as pellet extrusion for composites and thermoplastics, and direct energy deposition for metal alloys. Combining robotized additive processes with advanced software of path, parameters, and process planning, allows us to solve critical needs in highly advanced industrial sectors. From aerospace, to marine, to creative industries; from jigs, molds, to structural finished parts, and circular economy projects. We solve real needs, on real applications. Today, Caracol has a global presence and direct offices in 3 countries; with the largest industrial LFAM production center in Europe and its HQ (Milan, Italy), a production facility in Austin (TX) - USA, and a commercial office in Dubai - UAE.

Proxima Fusion is Europes leading fusion company, building the first generation of stellarator fusion power plants.

NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics. The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes. NanoPhoria’s lead product, NP-MP1 is an inhalable nano-in-micro formulation, delivering a proprietary peptide, first-in-class calcium channel modulator, for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome affecting the lives of millions worldwide.

Axelera AI delivers an AI-native game-changing hardware and software platform to accelerate artificial intelligence. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, UK and Italy and operations in 15 European countries . Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.

We develop ultra-high bandwidth, low latency optical interconnect transceivers used to reduce the infrastructure cost and energy consumption of generative AI, cellular, and strategic data transfer systems.

Nouscom is a clinical-stage biotech company redefining cancer immunotherapy through its proprietary viral vector platform. Headquartered in Basel, Switzerland, Nouscom develops both off-the-shelf and personalized neoantigen immunotherapies that activate robust and durable T cell responses in cancer patients. Our lead program, NOUS-209, is advancing toward registrational for cancer interception in Lynch Syndrome carriers, a transformative opportunity for these patients. The program has received positive regulatory feedback with a global registrational trial expected to launch in H1 2026. Nouscom’s second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. It has demonstrated clinical responses in metastatic melanoma patients and is supported by a fully automated GMP manufacturing process that enables scalable delivery within 8 weeks. Nouscom is supported by leading life sciences investors including 5AM Ventures, Andera Partners, M Ventures, Bpifrance, EQT Life Sciences, Indacos, Panakes, Revelation, Versant Ventures and XGen Ventures. Our platform is clinically validated in over 170 patients and offers unmatched immunogenicity, scalability, and safety — positioning Nouscom as a frontrunner in the next generation of cancer immunotherapy. 🔗 Learn more at http://www.nouscom.com

Genespire is a biotechnology company focused on the development of durable and transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners.

AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.

The evolution of manufacturing starts from solving the most demanding industrial needs: building large, complex, critical parts with more efficiency and sustainability. Caracol was born from the idea of pushing the limits of manufacturing, beyond what was possible. We brought that idea to life, combining robotics and additive manufacturing into a turnkey solution, which evolves the possibilities of production in terms of scale, shape, and materials. We developed integrated robotic platforms Heron and Vipra – which combine software, hardware, and automation – to manufacture parts with additive processes such as pellet extrusion for composites and thermoplastics, and direct energy deposition for metal alloys. Combining robotized additive processes with advanced software of path, parameters, and process planning, allows us to solve critical needs in highly advanced industrial sectors. From aerospace, to marine, to creative industries; from jigs, molds, to structural finished parts, and circular economy projects. We solve real needs, on real applications. Today, Caracol has a global presence and direct offices in 3 countries; with the largest industrial LFAM production center in Europe and its HQ (Milan, Italy), a production facility in Austin (TX) - USA, and a commercial office in Dubai - UAE.

Proxima Fusion is Europes leading fusion company, building the first generation of stellarator fusion power plants.

NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics. The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes. NanoPhoria’s lead product, NP-MP1 is an inhalable nano-in-micro formulation, delivering a proprietary peptide, first-in-class calcium channel modulator, for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome affecting the lives of millions worldwide.

Axelera AI delivers an AI-native game-changing hardware and software platform to accelerate artificial intelligence. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, UK and Italy and operations in 15 European countries . Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.